je.st
news
Home
› PixarBio Corporation Announces USFDA OPD Submission Of NeuroRelease TN For Orphan Drug Designation For Trigeminal Neuralgia
PixarBio Corporation Announces USFDA OPD Submission Of NeuroRelease TN For Orphan Drug Designation For Trigeminal Neuralgia
2015-11-03 03:42:29| drugdiscoveryonline Home Page
PixarBio Corporation recently announced that it has filed an application with the US FDA Office of Orphan Products Development, for orphan drug status of our NeuroRelease TN (NR-TN) drug candidate for the treatment of Trigeminal Neuralgia (TN)
Tags: corporation
drug
submission
announces
Category:Biotechnology and Pharmaceuticals